Evidence map›Paper›PMID 21050138›Full record

ArticleAntioxidants & redox signaling2011

Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.

Kotaro Kida, Marina Yamada, Kentaro Tokuda, Eizo Marutani, Manabu Kakinohana, Masao Kaneki, Fumito Ichinose

Abstract read
In one paragraph

Article in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Recent Advances in Molecular Research on Hydrogen Sulfide (HInternational journal of molecular sciences · 2022
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Hydrogen Sulfide Signaling in Neurodegenerative Movement Disorders.Handbook of experimental pharmacology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Black gas, bright future: HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  14. The role of gasotransmitters in Parkinson's disease: Interplay of nitric oxide, carbon monoxide, and hydrogen sulfide.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  15. Targeting macro- and micro-nutrient regulation of HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  16. Article
  17. Sulfide regulation and catabolism in health and disease.Signal transduction and targeted therapy · 2025
    Review
  18. Article
  19. Article
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kotaro KidaDepartment of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Marina Yamada
Kentaro Tokuda
Eizo Marutani
Manabu Kakinohana
Masao Kaneki
Fumito Ichinose
Harvard University · USMassachusetts General Hospital · US

Funding

Inducible Nitric Oxide Synthase and Insulin ResistanceR01DK058127 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KANEKI, MASAO · 2002 to 2009
$2.1M
IMPACT OF HYDROGEN SULFIDE ON OUTCOME OF CARDIAC ARREST AND CARDIOPULMONARY RESUSR01HL101930 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ICHINOSE, FUMITO · 2010 to 2014
$2.1M
NHLBI NIH HHS HL101930NHLBI NIH HHS R01 HL101930NIDDK NIH HHS DK05827NIDDK NIH HHS R01 DK058127
6 · The paper itself

Abstract

Parkinson's disease is one of the major neurodegenerative disorders. Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can cause Parkinson's disease-like symptoms and biochemical changes in humans and animals. Hydrogen sulfide (H(2)S) has been shown to protect neurons. The goal of this study was to examine the effects of inhaled H(2)S in a mouse model of Parkinson's disease induced by MPTP. Male C57BL/6J mice received MPTP at 80 mg/kg and breathed air with or without 40 ppm H(2)S for 8 h/day for 7 days. Administration of MPTP induced movement disorder and decreased tyrosine hydroxylase (TH)-containing neurons in the substantia nigra and striatum in mice that breathed air. Inhalation of H(2)S prevented the MPTP-induced movement disorder and the degeneration of TH-containing neurons. Inhaled H(2)S also prevented apoptosis of the TH-containing neurons and gliosis in nigrostriatal region after administration of MPTP. The neuroprotective effect of inhaled H(2)S after MPTP administration was associated with upregulation of genes encoding antioxidant proteins, including heme oxygenase-1 and glutamate-cysteine ligase. These observations suggest that inhaled H(2)S prevents neurodegeneration in a mouse model of Parkinson's disease induced by MPTP, potentially via upregulation of antioxidant defense mechanisms and inhibition of inflammation and apoptosis in the brain.

Indexed as

Disease Models, Animal1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAdministration, InhalationAnimalsApoptosisBase SequenceBehavior, AnimalBlotting, WesternBody TemperatureDNA PrimersHydrogen SulfideMaleMiceMice, Inbred C57BLMovement DisordersNeurodegenerative Diseases1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDNA PrimersHydrogen Sulfide

Identifiers

PMID21050138
PMCPMC3118610
OpenAlexW1999088334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.